Why the study?
Does an ACE inhibitor or ARB reduce new-onset type 2 diabetes in patients with hypertension, coronary artery disease, or heart failure?
Does an ACE inhibitor or ARB reduce new-onset type 2 diabetes in patients with hypertension, coronary artery disease, or heart failure?
ACE inhibitors and ARBs significantly reduce the odds of developing new-onset type 2 diabetes compared to placebo or routine therapy across various indications.
No takes yet. Share an insight, caveat, or question.
ACEI/ARB therapy should be prioritized to lower diabetes risk in hypertension or CVD; confirms benefit across indications in Level 1 evidence.
Gillespie et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: